Adicet Bio (ACET) Q3 2026 earnings review
Adicet Bio cuts research spending, but secondary trial timelines slip
Adicet Bio, a clinical-stage developer of immune cell therapies, cut its cash usage while advancing its lead lupus treatment toward a final-stage trial. Third-quarter research spending fell 32% from a year ago, which helped reduce quarterly cash usage to about $17 million by our math. Chief executive Chen Schor highlighted Phase 1 lupus results where 54% of patients reached complete remission at one year, and the company began setting up a final-stage kidney lupus study.
| Research and development expenses | $15.6M -32% from a year ago |
|---|---|
| Net loss | $18.9M -30% from a year ago |
| Cash and short-term investments | $100.9M $118.2M last quarter |
| Cash funding outlook | Unchanged funds operations into the second half of 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because progress in the lead lupus program was offset by timeline delays across the rest of the pipeline. The biotechnology group met its third-quarter goal for lupus data and started final-stage trial preparations, so its main asset stays on track. The bad news: management pushed systemic sclerosis data and prostate cancer trial enrollment from late 2026 into the first half of 2027, and dropped any mention of its rheumatoid arthritis trial.
The question now is whether Adicet Bio can deliver pivotal lupus agreement and early data from its delayed trials before its $101 million cash pile runs low in the second half of 2027. If the Food and Drug Administration allows non-kidney lupus patients into the final-stage study and spending stays near $17 million a quarter, the company can reach early 2027 readouts from a position of strength; if starting three trials lifts cash usage toward the $25 million quarterly rate implied by the outlook, it will need fresh capital sooner. First-quarter 2027 regulatory updates and fourth-quarter cash usage will decide.
🐂 Bull Case
Lupus Trial Results Support Wider Final-Stage Testing
Adicet Bio is testing prula-cel, an off-the-shelf immune cell therapy, in patients with severe lupus. Chief executive Chen Schor said the September trial update showed a "deep immune reset and a favorable safety profile supporting outpatient administration" following the "complete discontinuation of immunosuppressants". The drug developer started setting up a final-stage trial in lupus nephritis (LN), which is lupus with kidney damage.
- Complete kidney response at 12 months: 50% of evaluable LN patients
- Overall lupus remission at 12 months: 54% of evaluable patients across both groups
- Medication reduction: all 22 patients stopped immune-suppressing drugs, and 21 cut steroid doses to 5 mg or less
- Safety: zero severe immune or neurological side effects across 22 patients
Because remission rates were high across the whole group, management will meet the Food and Drug Administration in the fourth quarter. The biotechnology group wants to add lupus patients without kidney damage to its final-stage program, which would enlarge the potential market for prula-cel.
What to watch: the regulatory update and 12-month data from all 22 patients in the first quarter of 2027. Agreement from regulators to include non-kidney lupus patients in the final-stage trial would widen the drug's commercial reach.
Research Spending Cuts Slow Quarterly Cash Usage
As a clinical-stage biotechnology company with no product sales, Adicet Bio relies on cost discipline to preserve its cash balance. In the third quarter, the cell-therapy developer reduced total operating expenses by 29.2% from a year ago to $19.8 million, and by 11.2% from the second quarter. Research and development costs drove the savings, falling 31.6% from a year ago to $15.6 million.
Lower research spending reduced the company's quarterly cash usage to $17.2 million by our math, down from $19.4 million in the second quarter and $20.9 million in the first quarter. This slower spending rate preserves capital while the team prepares its lead lupus therapy for larger studies.
What to watch: fourth-quarter research and development expenses when full-year results arrive in early 2027. A rise in quarterly spending above $22 million would show that starting the final-stage lupus trial is reversing the recent cost savings.
🐻 Bear Case
Three Clinical Timelines Pushed Into 2027
Schor said 2027 will be a catalyst-rich year for the drug developer. However, several of those 2027 milestones are programs that Adicet Bio previously planned to deliver in the second half of 2026. The company pushed back timelines across both its autoimmune and cancer pipelines without explaining the delays.
- Systemic sclerosis trial readout: moved to the second quarter of 2027, from a prior target of the second half of 2026
- ADI-212 prostate cancer trial enrollment: moved to the first quarter of 2027, from the fourth quarter of 2026
- In vivo CAR-T update: shifted to entering the clinic in the second half of 2027, while a platform update planned for the second half of 2026 did not appear
- Rheumatoid arthritis trial: omitted from the third-quarter release after being scheduled for a second-half 2026 readout
These shifts matter because they compress multiple trial readouts into the same 2027 window when the company's cash reserves are set to run low. Delays in early-stage studies also reduce the backup options available if the lead lupus program faces regulatory hurdles.
What to watch: first-quarter 2027 confirmation that the first prostate cancer patient has enrolled in the ADI-212 study. Another delay would indicate operational bottlenecks in starting new clinical sites.
Cash Horizon Leaves Little Room for Trial Costs
Adicet Bio ended September with $100.9 million in cash and short-term investments. The biotechnology group reiterated that this balance will fund operations "into the second half of 2027". By our math, the third-quarter cash usage of $17.2 million would last nearly six quarters, but the company's own timeline points to an average quarterly usage of about $25.2 million over the next four quarters.
That implied increase in spending matches the workload ahead. The company is starting a final-stage lupus study enrolling a "double-digit number of patients", opening a Phase 1 prostate cancer trial in early 2027, and bringing an in vivo therapy into human testing in late 2027. Because clinical trials require multi-year funding commitments, the narrowing cash window creates pressure to raise money soon.
What to watch: the year-end cash balance and 2027 cash horizon in the fourth-quarter report. Entering 2027 with less than 12 months of funding remaining would point to a near-term share sale or partnership.
👓 Other Themes
FDA Clears Prostate Cancer Therapy for Human Trials
In August 2026, the Food and Drug Administration cleared Adicet Bio to begin human testing of ADI-212, an off-the-shelf cell therapy for advanced prostate cancer, and granted it Fast Track status in September. The treatment uses "multiple platform enhancements by incorporating gene-editing" to help immune cells survive inside solid tumors. The company is setting up trial sites and plans to enroll the first patient in early 2027.
💲 Other KPIs
Working capital — short-term assets minus short-term liabilities — fell 15.9% from $102.8 million in the second quarter. The decline has stayed steady over the past three quarters, dropping by $17.6 million in the first quarter, $19.0 million in the second, and $16.3 million in the third as the company spends down its treasury securities to fund research.
Weighted-average common shares rose 88.8% from 5.69 million a year ago because the biotechnology company sold equity in a $74.8 million offering in October 2025. Compared with the first and second quarters of 2026, the share count was unchanged at 10.75 million. The higher share count cut the net loss per share by 62.7% to $1.76.
Overhead and administrative costs fell 18.2% from $5.10 million a year ago, continuing a year-over-year decline seen in the first and second quarters from lower staffing and stock-compensation costs. Compared with the second quarter's $3.85 million, however, administrative spending rose 8.3%. Stock-based compensation made up $0.7 million of the third-quarter total.
🔮 Guidance
Unchanged. Management still expects its $100.9 million in cash and short-term investments to fund operations into the second half of 2027, the same horizon it has held since raising $74.8 million in October 2025. By our math, funding operations to the third quarter of 2027 allows an average quarterly cash usage of $25.2 million, up from $17.2 million in the third quarter.
❓ Key Questions
What is the status of the rheumatoid arthritis trial?
Adicet Bio previously planned to share clinical data from its Phase 1 rheumatoid arthritis study in the second half of 2026, but the third-quarter release did not mention the trial. Investors need to know if the study is still enrolling or paused.
Why did systemic sclerosis data move to mid-2027?
The company pushed the Phase 1 readout for prula-cel in systemic sclerosis from the second half of 2026 to the second quarter of 2027. Explaining whether patient enrollment or follow-up duration caused the shift would clarify demand for the trial.
How many patients will the final-stage lupus trial require?
Management said the single-arm final-stage study in lupus nephritis will enroll a "double-digit number of patients". The exact target between 10 and 99 patients will determine both the trial's cost and how long enrollment takes.
What happened to the 2026 in vivo platform update?
In the second quarter, Adicet Bio planned a comprehensive update on its in vivo CAR-T platform for the second half of 2026. The company now says the first candidate will enter the clinic in late 2027 without detailing the preclinical data.